News Articles Tagged: ESR1 Mutation

Elacestrant Intermediate: The Foundation for Next-Generation Breast Cancer Treatment

Explore the significance of 6-(2-amino-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol as an Elacestrant intermediate and its impact on advanced breast cancer treatment, supported by NINGBO INNO PHARMCHEM CO.,LTD.

The Role of N-Ethyl-4-Formyl-Benzeneacetamide in Advancing Elacestrant Therapy for ESR1+ Breast Cancer

NINGBO INNO PHARMCHEM CO.,LTD. explores the critical function of N-Ethyl-4-Formyl-Benzeneacetamide (CAS 2477812-42-1) as an essential intermediate in the production of Elacestrant, a targeted treatment for ESR1-mutated breast cancer.

Advancing Cancer Treatment: The Significance of ESR1 Mutations and Targeted Therapies

Explore how understanding ESR1 mutations in breast cancer has led to the development of targeted therapies like Elacestrant, supported by intermediates from NINGBO INNO PHARMCHEM.